Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

Parkinson's Disease Clinical Trial

Official title:

Randomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00957918
• Other study ID #: NP002-09-001
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: August 11, 2009
• Last updated: September 26, 2011
• Start date: October 2009
• Est. completion date: September 2010

Study information

• Verified date: September 2011
• Source: Neuraltus Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The study is designed to answer the question: will nicotine at doses that do not cause serious side effects, show feasibility in treatment of levodopa-induced dyskinesia in patients with Parkinson's disease?

Description:

Nicotine will be employed at daily doses lower than those available OTC as smoking-cessation patches, in parkinsonian patients experiencing disabling dyskinesias due to their levodopa treatment. The principal adverse effect from this dose level of nicotine is expected to be nausea on acute administration to nicotine-naive patients. Because tolerance to the effects of nicotine is achieved by repeated dose, the study is designed to gradually escalate from 6 to 24 mg per day, taken in 6 separate oral doses of 6 mg each. The study is designed to see if doses which can be tolerated by parkinsonian patients will also reduce the severity and frequency of the dyskinesias experienced following administration of levodopa, the gold standard medication for Parkinson's disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: September 2010
• Est. primary completion date: September 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 30 Years to 83 Years

Eligibility

Inclusion Criteria:

• clinical diagnosis of probable idiopathic Parkinson's disease

• in stable health

• male and female aged 30-83 yrs

• Hoehn and Yahr stage II through IV inclusive

• levodopa-induced dyskinesias present greater than 25% of waking day; rating equal or greater than 2 on item 32 of UPDRS

• dyskinesias moderately or severely disabling as determined by a rating of equal or greater than 2 on item 33 of UPDRS

• Mini-Mental state (MMSE) score of equal or greater than 26

• on a stable dose of levodopa for at least 30 days

• if subjects are taking dopamine antagonists, amantadine, MAO-B inhibitors (rasagiline only) or COMT inhibitors, doses must have been stable for at least 30 days

Exclusion Criteria:

• Secondary or non-idiopathic Parkinson's disease

• Subjects with parkinsonian symptoms who do not respond to levodopa therapy

• history of schizophrenia, or other DSM-IV TR axis 1 diagnosis sufficient to interfere with or affect study conduct or interpretation of results

• any history (past 5 years) of suicide or suicide attempt or thoughts or urges of suicide on direct questioning

• subjects who score 2 or higher on a single module of the Jay MIDI scale

• moderate or severe hallucinations, psychoses or delusions

• any medical condition or lab abnormality presenting an unwarranted risk in the opinion of the Investigator

• history of HIV positivity, AIDS, or active hepatitis determined by subject report

• female who is pregnant or breastfeeding

• female of childbearing potential not using double barrier method of birth control throughout the duration of the study

• receipt of a neurosurgical intervention (e.g. brain surgery)related to Parkinson's disease or any neurosurgical procedure sufficient to interfere with study conduct or interpretation of results

• must not have systolic blood pressure =150; diastolic =95.

• must not have ECG at screening judged clinically significantly abnormal by investigator

• must not have QTc > 450 msec at ECG screen

• must not have current angina pectoris, history of ventricular arrhythmias, uncontrolled hyperthyroidism, known or suspected pheochromocytoma, symptomatic vasospastic disease, or active peptic ulcer

• must not have a history of stroke, transient ischemic attack (TIA) or myocardial infarction within the last 2 years

• must not have current drug or alcohol abuse within the last two years. Acceptable alcohol use is no more than 3 ounces of alcohol, 3 beers or 2 glasses of wine per day.

• must not be participating in another drug trial or have participated in another drug study in the last 30 days. Observational trials with no intervention are acceptable provided permission is obtained from the other study sponsor in writing.

• must not be unwilling or unable to swallow capsules

• must not have a positive urine test for cotinine at screening

• must not be a smoker, previous (less than 5 years since cessation) smoker or have regular exposure to second hand smoke

• must not be allergic to capsule excipients

• must not be allergic to ondansetron. If allergic, they may participate provided they understand there is no rescue medication for potential nausea or vomiting during the study

• must not have known sensitivity to nicotine or nicotine-containing products

• must not be taking any of the following medications or substances within a minimum of 30 days: nicotine, any form; CYP2A6 inducers or inhibitors during the course of the study or within 30 days of the planned initial dose (your investigator will have a full list of these drugs); Monoamine oxidase inhibitors (with the exception of rasagiline, which is allowed)(your investigator will have a full list of these drugs); apokyn (apomorphine), due to its contraindication with ondansetron); warfarin.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dyskinesias
• Parkinson Disease
• Parkinson's Disease

Intervention

Drug:
• nicotine
Oral capsule self administered in escalating doses from 1 mg to 6 mg, 4 times a day. Each dose is is taken for two weeks, except the highest dose, which is taken for 4 weeks. At the end of 10 weeks, the dose is tapered down over 9 days. Subject is continued on study through week 14.

Other:
• placebo comparator
oral capsules containing only excipient will be self-administered with the same regimen as the active drug, 4 times a day, approximately every 6 hours for 10 weeks and nine days. Study is continued through week 14.

Locations

Country	Name	City	State
United States	Parkinson's Disease & Movement Disorders Ctr of Boca Raton	Boca Raton	Florida
United States	David L. Kreitzman, M.D., P.C.	Commack	New York
United States	Duke University Medical Center, Department of Neurology	Durham	North Carolina
United States	Colorado Neurological Institute	Englewood	Colorado
United States	108-14 72nd Ave, Second floor	Forest Hills	New York
United States	Strurers Parkinson's Center	Golden Valley	Minnesota
United States	Keck/USC School of Medicine -Department of Neurology	Los Angelis	California
United States	Collier Neurologic Specialists, LLC	Naples	Florida
United States	Pacific Neuroscience Medical Group	Oxnard	California
United States	Parkinson's Disease and Movement Center, Penn Comprehensive Neuroscience Center	Philadelphia	Pennsylvania
United States	Barrow Neurology Clinics at St. Joseph's Hospital and Medical Center	Phoenix	Arizona
United States	The Movement Disordedr Clinic of Oklahoma	Tusla	Oklahoma

Sponsors (1)

Lead Sponsor	Collaborator
Neuraltus Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	frequency and severity of adverse events, active vs placebo		Every two weeks during dosing (week 0 to week 12) and weekly thereafter for 2 weeks following cessation of dosing	Yes
Primary	measure of impulse control (rMIDI), active vs placebo		at screening and 4 weeks, 10 weeks, 12 weeks and 14 weeks	Yes
Secondary	measure of frequency and severity of dyskinesia (USDysRS), active vs placebo		At screen and every two weeks through week 10	Yes
Secondary	Parkinson's disease severity (UPDRS part II,III,IV), active vs placebo		At screen and every two weeks through week 10	No